HR 7407 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Prohibiting Tianeptine and Other Dangerous Products Act of 2026
To amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements.
Summary
The bill amends the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements. It prohibits introducing products into interstate commerce that are marketed as dietary supplements but do not meet the legal definition of dietary supplements, and prohibits dietary supplements prepared by or under the direction of a person debarred from food or drug manufacturing. The bill expands import exclusion authority to include products violating these new prohibitions. It also expands seizure authority to allow the FDA to seize products that violate these new requirements, similar to existing seizure authority for other types of prohibited products.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Pallone, Frank [D-NJ-6] (D-NJ)
Money behind the sponsor
Top reported contributors to Frank Pallone’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- COX ENTERPRISES $28,000
- AMNEAL PHARMACEUTICALS $17,200
- JOHNSON & JOHNSON $15,500
- RESOLUTION PUBLIC AFFAIRS $14,800
- NULL $14,375
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Frank Pallone → · Outside spending →
Actions (2)
- Feb 5, 2026 Referred to the House Committee on Energy and Commerce. · house
- Feb 5, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
February 5, 2026
Mr. Pallone introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Prohibiting Tianeptine and Other Dangerous Products Act of 2026”.
SEC. 2. NEW PROHIBITED ACTS RELATING TO DIETARY SUPPLEMENTS.
(a) In General.—Section 301 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amended by adding at the end the following: “(jjj) The introduction or delivery for introduction into interstate commerce of any product marketed as a dietary supplement that does not meet the definition of a dietary supplement under section 201(ff). “(kkk) The introduction or delivery for introduction into interstate commerce of a dietary supplement that has been prepared, packed, or held using the assistance of, or at the direction of, a person debarred under section 306.”.
(b) New Import Exclusion.—Section 801(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a)) is amended in paragraph (3) of the third sentence, by striking “section 301(ll)” and inserting “paragraph (ll), (jjj), or (kkk) of section 301”.
(c) New Seizure Authorities.—Section 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 334) is amended—
(1) in subsection (a)(1), in the first sentence, by striking “section section 301(ll), 404, or 505” and inserting “paragraph (ll), (jjj), or (kkk) of section 301, section 404, or section 505”; and
(2) in subsection (d)(1), in the first sentence, by inserting “, or product in violation of paragraph (jjj) or (kkk) of section 301,” after “condemned under this section”. <all>
Comments